Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925952 | 0.87 | TSHR (0.48) | TSHRLMNANPSR1SLC40A1CLK1 | |
| SCHEMBL3935555 | 0.85 | ALDH1A1 (0.47) | SLC40A1PGRALDH1A1 | |
| SCHEMBL3924006 | 0.83 | SLC22A12 (0.49) | LMNASCN9A | |
| SCHEMBL3935302 | 0.81 | HSD11B1 (0.42) | TSHRLMNANPSR1SLC40A1NR3C1 | |
| SCHEMBL3927414 | 0.77 | SLC22A12 (0.46) | SCN9A | |
| SCHEMBL3926003 | 0.75 | SCN9A (0.43) | SCN9AKDM4E | |
| SCHEMBL3935360 | 0.74 | MEN1 (0.43) | TSHRLMNANPSR1SLC40A1CLK1 | |
| SCHEMBL3935299 | 0.73 | TSHR (0.45) | TSHRLMNANPSR1SLC40A1CLK1 | |
| SCHEMBL3923000 | 0.73 | SLC22A12 (0.41) | LMNASCN9AKDM4E | |
| SCHEMBL3925060 | 0.73 | HSD11B1 (0.47) | LMNASLC40A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | claimed |
| JP-2008515826-A | — | — | 2008-05-15 | — | — | JP | claimed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | claimed |
| EP-1799647-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-27 | — | — | EP | claimed |
| WO-2006037501-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | TSHR 1406/4885LMNA 862/4885NPSR1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.